Sequential Application of Emicizumab and Factor VIII Concentrate for Patients with Hemophilia A: A Pilot Study with Zero Annual Bleeding Rate

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230705005

Enrollment

Registered

2023-07-05

Start date

2023-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with hemophilia A without inhibitor. hemophilia A, no inhibitor

Interventions

Patients with hemophilia A without inhibitor were recruited. Sequential use of monthly low dose emicizumab in the first week and factor VIII concentrate in the 4th week was provided. Patients were clo

Active Comparator Drug

Prophylaxis arm

Eligibility

Sex/Gender

Male

Age

2 Years to 60 Years

Inclusion criteria

Inclusion criteria: Hemophilia A without inhibitor on prophylaxis.

Exclusion criteria

Exclusion criteria: Congenital and acquired hemophilia A with inhibitor.

Design outcomes

Primary

Measure	Time frame
Annual bleeding rate 1 year Number and sites of bleeding	—

Secondary

Measure	Time frame
Musculoskeletal system before and 1 year after HJHS	—

Countries

Thailand

Contacts

Public ContactAmpaiwan Chuansumrit

Faculty of Medicine Ramathibodi Hospital

ampaiwan.jua@mahidol.ac.th022011749

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026